Absence of correlation between mental disorders and high-dose buprenorphine: A case-control study;Absence de corrélation entre troubles psychiques et injection de buprénorphine haut dosage: Étude cas-témoin

Presse Medicale

Volumn 34, Issue 10, 2005, Pages 711-718

  Phan, Olivier ^a   Sanchez, Mario ^b,c   Bouthillon Heitzmann, Pascale ^a  

^a INSTITUT MUTUALISTE MONTSOURIS   (France)

^b Institut Baron Maurice de Rothschild Pour le Traitement et la Recherche Dans Les Addictions   (France)

^c Institut Baron Maurice de Rothschild Pour le Traitement et la Recherche Dans Les Addictions   (France)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; ALCOHOL; AMPHETAMINE DERIVATIVE; BENZODIAZEPINE DERIVATIVE; BUPRENORPHINE; COCAINE; DIAMORPHINE; ILLICIT DRUG; PSYCHEDELIC AGENT; PSYCHOTROPIC AGENT;

ADAPTATION; ADULT; ARTICLE; CASE CONTROL STUDY; CONTROLLED STUDY; DRUG DEPENDENCE TREATMENT; DRUG EFFICACY; DRUG MEGADOSE; DRUG MISUSE; DRUG SUBSTITUTION; FEMALE; FRANCE; HEPATITIS C; HEROIN DEPENDENCE; HUMAN; INTRAVENOUS DRUG ABUSE; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MENTAL INSTABILITY; MULTIPLE DRUG ABUSE; OPIATE ADDICTION; PERSONALITY DISORDER; PUBLIC HEALTH;

EID: 20944442387     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0755-4982(05)84024-2     Document Type: Article

References (28)

1. Auriacombe M, Fatseas M, Dubernet J, Daulouede JP, Tignol J. French field experience with buprenorphine. Am J Addict 2004; 13 Suppl 1:S17-28.
2. Phénomènes émergents liés aux drogues. Quatrième rapport national du dispositif TREND, OFDT, Paris, juin 2003.
3. Usages non substitutifs de la Bupŕnorphine haut dosage, Investigation meńe en France en 2002-2003, TREND, OFDT, Paris, juin 2004.
4. Strat́gies th́rapeutiques pour les personnes d́pendantes des opiaćs: place des traitements de substitution. Conf́rence de consensus. Presse Med 2004; 33; 18 (Suppl.): 41-7.
5. Varescon I, Vidal Trecan G, Nabet N, Boissonnas A. Substitution et ḿsusage: l'injection intraveineuse de bupŕnorphine haut dosage, L'Enćphale 2002; XXVIII: 397-402, cahier 1.
6. Vidal-Trecan G, Varescon I, Nabet N, Boissonnas A. Intravenous use of precribed sublingual buprenorphine tablets by drug users receiving maintenance therapy in France. Drug Alcohol Depend 2003; 69: 175-81.
7. Petitjean S, Stohler R, Deglon JJ, Livoti S, Waldvogel D, Uehlinger C et al. Double-blind randomized trial of buprenorphine and methadone in opiate dependence. Drug Alcohol Depend 2001; 62: 97-104.
8. Shinderman M, Maxwell S, Brawand-Amey M, Golay KP, Baumann P, Eap CB. Cytochrome P4503A4 metabolic activity, methadone blood concentrations, and methadone doses. Drug Alcohol Depend 2003; 69: 205-11.
9. Eap CB, Bourquin M, Martin J, Spagnoli J, Livoti S, Powell K et al. Plasma concentrations of the enantiomers of methadone and therapeutic response in methadone maintenance treatment. Drug Alcohol Depend 2000; 61: 47-54.
10. Ferrari A, Coccia CP, Bertolini A, Sternieri E. Methadone-metabolism, pharmacokinetics and interactions. Pharmacol Res 2004; 50: 551-9.
11. Gerra G, Sorella F, Zaimovic A, Moi G, Bussandri M, Bubici C, Bertacca S. Buprenorphine versus methadone for opioid dependence: predictor variables for treatment outcome. Drug Alcohol Depend 2004; 75: 37-45.
12. Enquête Subgeo, Laboratoire Schering Plough, 2002.
13. Vidal-Trecan G, Nabet N, Varescon L, Boissonnas A. Usagers de drogues injectables et prescription de substitution: d́rives. Congrès de l'Adelf 2000.
14. Courty P. High dosage buprenorphine and injection practices. A study of 303 patients. Ann Med Interne 2003; 154: S35-45.
15. Obadia Y, Perrin V, Feroni I, Vlahov D, Moatti JP. Injecting misuse of buprenorphine among French drug users. Addiction 2001; 96: 267-72.
16. Carrieri MP, Key D, Loundou A, Lepeu G, Sobel A, Obadia Y. The MANIF-2000 Study Group. Evaluation of buprenorphine maintenance treatment in a French cohort of HIV-infected injecting drug users. Drug Alcohol Depend 2003; 72: 13-21.
17. Lecrubier Y, Sheehan DV, Weiller E, Amorin P, Bonora I, Harnet-Sheehan K et al. The MINI International Neuropsychiatric Interview (MINI) a short diagnostic structured interview: Reliability and validity according to the CIDI. European Psychiatry 1997; 12: 224-31.
18. Beck AT. Assessment of depression: the depression inventory. In Psychological Measurements in Psychopharmacology. P. Pichot ed. Mod. Probl. Pharmacopsychiatry, Paris Basel, 1974, p 151-9.
19. Zuckerman M. Behavioural expression and biosocial bases of sensation seeking. New York. Cambridge University Press, 1994.
20. Kanof PD, Aronson MJ, Nes R. Organic mood syndrome associated with detoxification from ḿthadone maintenance. Am J Psychiatry 1993; 150: 423-35.
21. Rounsaville BJ, Weissman M, Kleber H. Diagnosis and symptom of depression in opiate addicts. Arch Gen Psychiatry 1982; 39: 43-9.
22. Fontaa V, Bronner C. Persistent injecting practices in subjects on methadone or buprenorphine maintenance therapy. A study of 600 cases. Ann Med Interne 2001; 152 Suppl 7: 59-69.
23. Brunelle E. Analysis of drug consumption among ambulatory patients in a drug agency of Northern France (Lens). Ann Med Interne 2003; 154: 515-23.
24. Vidal-Trecan G, Varescon-Pousson I, Gagnière B, Tcherny-Lessenot S, Madariaga E, Boissonnas A. Association between first injection risk behaviors and hepatitis C seropositivity among injecting drug users. Ann Med Int 2002; 53: 219-25.
25. Blanchon T, Boissonnas A, Varescon I, Vidal-Trecan G. Homelessness and high-dosage buprenorphine misuse. Subst use Misuse 2003; 38: 429-42.
26. Reynaud M, Petit G, Potard D, Courty P. Six deaths linked to concomitant use of buprenorphine and benzodiazepines. Addiction 1998; 93: 1385-92.
27. Kintz P. Deaths involving buprenorphine: a compendium of french cases. Forensic Sci Int 2001; 121: 65-9.
28. Kintz P. A new series of 13 buprenorphine-related deaths. Clinical Biochemistry 2002; 35: 513-16.